Pharmaceutical Market Europe • March 2023 • 34-36
APPOINTMENTS
Roche Pharmaceuticals
Teresa Graham
Roche Pharmaceuticals has appointed Teresa Graham as chief executive officer. Graham originally joined the company’s Genentech unit in 2005 in product management, and advanced to the position of vice president bio-oncology sales and marketing, before transferring to Roche's Basel headquarters in Switzerland to take up her current role as head of global product strategy.
Graham is also a global board member for the Healthcare Businesswomen's Association, where she has served in multiple capacities for more than a decade.
In her new role, Graham will replace Thomas Schinecker, who is serving as a transitional pharma head after Bill Anderson left the company at the end of 2022. Schinecker, who was previously Roche’s diagnostics chief, will replace Severin Schwan as CEO of the Roche group. Schwan, who has headed the company for 15 years, will then transition to the role of chairman.
Bayer AG
Bill Anderson
Bayer AG has appointed Bill Anderson as chief executive officer. Anderson has a strong pharma background, having worked in the life sciences industry for the past 25 years. Most recently, he served as CEO of Roche’s pharmaceuticals division, prior to which he was CEO of Genentech. Previously, Anderson held several senior leadership positions in general management, product development and finance at Biogen.
Vir Biotechnology
Marianne De Backer
Vir Biotechnology has appointed Marianne De Backer as chief executive officer. de Backer has more than 20 years of broad international leadership experience. She joins from Bayer Pharmaceuticals, where she was previously executive vice president, head of pharmaceuticals strategy, business development and licensing/open innovation, as well as a member of the company’s executive committee.
Astellas
Naoki Okamura
Astellas has appointed Naoki Okamura as chief executive officer. Currently chief strategy officer, Okamura has an extensive history with the company, having held a variety of senior leadership roles including corporate vice president, head of global business development and vice president, corporate planning. Previously he was also president and chief executive officer of OSI Pharmaceuticals.
Oncopeptides AB
Monica Shaw
Oncopeptides AB has appointed Monica Shaw as chief executive officer. Shaw brings extensive executive leadership experience to the role, having worked at companies including GSK and LEO Pharma. She also has a strong track record of bringing more than 15 products through phase 3 to successful commercialisation, and a broad therapeutic area knowledge from previous positions as a physician and within industry.
Novartis
Gilbert Ghostine
Novartis has appointed Gilbert Ghostine as chairman-designate of the new board of Sandoz, following its spin-off from the company later this year. Ghostine has extensive experience, having held executive and senior leadership positions at Firmenich and Diageo in a career spanning three decades. He has served as chief executive officer of Geneva-based Firmenich since 2014.
Roche
Levi Garraway
Roche has appointed Levi Garraway to its enlarged corporate executive committee. Garraway joined the company in 2019 in his current role as chief medical officer and executive vice president, global product development. Previously he was director of the Joint Center for Cancer Precision Medicine, spanning Harvard teaching hospitals and the Broad Institute of MIT and Harvard.
Gavi
Muhammad Ali Pate
Gavi has appointed Muhammad Ali Pate as chief executive officer of the vaccine alliance. A medical doctor trained in both internal medicine and infectious diseases, Pate has served in a variety of roles including Nigeria’s Minister of State for Health, and global director for health, nutrition and population, and director of the global financing facility at the World Bank.
Johnson & Johnson
Paula Johnson
Johnson & Johnson has appointed Paula Johnson to its board of directors. Johnson is currently president of Wellesley College and has held several leadership roles in her career. She was most recently the Grayce A Young Family Professor of Medicine in Women’s Health at Harvard Medical School and a professor of epidemiology at the Harvard TH Chan School of Health.
Johnson & Johnson
John Reed
Johnson & Johnson has appointed John Reed as executive vice president of pharmaceuticals, R&D. Reed joins the company with more than 35 years of biomedical research leadership experience, having most recently served as executive vice president, global head of research and development for Sanofi, where he was also a member of the executive committee. Prior to that, Reed served as global head of pharmaceutical research and early development at Roche, where he was also a member of its executive committee. He has also held the position of chief executive officer at an independent, non-profit biomedical research institute in La Jolla, California in the US. Reed has authored more than 900 research publications and holds over 130 patents. He has been recognised among the top ten most cited researchers in life sciences and medicine, and is also a Fellow of the American Association for the Advancement of Science.
LEO Pharma
Kasper Künzel
LEO Pharma has appointed Kasper Künzel as interim vice president and general manager for its UK and Ireland business. Künzel joins the company with over 17 years of pharmaceutical experience, having previously taken on local and global leadership positions across LEO. This includes general manager in South Korea, vice president of corporate transformation and director of R&D business finance.
Boehringer Ingelheim UK & Ireland
Vani Manja
Boehringer Ingelheim UK & Ireland has appointed Vani Manja as country managing director and head of human pharma. Manja has been with the company for over 11 years in leadership roles in Germany, the US and most recently in India, where she served as general manager. Previously Manja worked in leadership roles at Becton Dickinson as senior global market segment director and as Associate Principle at McKinsey.
Abivax SA
Sheldon Sloan
Abivax SA has appointed Sheldon Sloan as chief medical officer. Sloan brings over 30 years of experience in academia and the biopharmaceutical industry to the role, having spent the last 25 years in large pharmaceutical and biotech companies, including 15 years in leading positions at Johnson & Johnson, followed by Arena Pharmaceuticals and then Pfizer as programme lead for Etrasimod UC.
Wellcome Sanger Institute
Matt Hurles
The Wellcome Sanger Institute has appointed Matt Hurles as director. Hurles has been head of the institute’s human genetics programme since 2017, focusing on the genetic causes of severe developmental disorders and understanding how DNA mutates through generations. He was elected as fellow of the UK Academy of Medical Sciences in 2017 and fellow of the Royal Society in 2019.
SpyBiotech
Eddie Gray
SpyBiotech has appointed Eddie Gray as chairman of its board of directors. Gray joins the board as an independent director. He has over 40 years of global experience in the life sciences industry, 25 of which have been with GSK. Gray also served as chief executive officer of Dynavax Technologies, and chair of the UK government’s COVID-19 Antivirals Taskforce during the peak of the pandemic.
Bausch + Lomb
Brent Saunders
Bausch + Lomb has appointed Brent Saunders as chief executive officer and chair of the board of directors. Saunders returns to the company after having served as its CEO from 2010 to 2013. In total, he brings over 25 years of leadership experience in healthcare, holding president, CEO and chairman roles, among others, at several global pharmaceutical and healthcare companies.
Elligo Health Research
Dawn Sauro
Elligo Health Research has appointed Dawn Sauro as chief operating officer. Sauro has over 30 years of drug and device development experience, including working for sites, sponsors and clinical research organisations. She most recently served as Elligo’s executive vice president, research strategy. Prior to this, she was chief development officer at Clinipace Clinical Research (now Caidya).
Alira Health
Annabel de Maria
Alira Health has appointed Annabel de Maria as chief patient officer. Maria joins the company with extensive experience, 20 years of which have been within the healthcare industry. She originally joined Alira in 2020 as vice president of patient engagement, prior to which she served as head of corporate communications at Almirall and head of media relations Europe at Nestlé Purina.
OPEN Health
Lisa Dodman
OPEN Health has appointed Lisa Dodman as chief people officer. Over a career spanning more than 25 years, Dodman has held numerous senior HR roles in a variety of organisations within the software industry. In her new role, she will be responsible for leading the company's people strategy including recruitment, learning and development, and business partnering.
Havas Health & You
Alex Okada
Havas Health & You has appointed Alex Okada as chief creative officer of Havas Lynx Group. Okada brings extensive experience to his new role, having led creative work across five continents. He most recently held the position of executive creative director for international accounts at MullenLowe and has also held CCO level positions at Publicis, Leo Burnett and McCann Erickson.
CREATION.co
Mary Fletcher-Louis
CREATION.co has appointed Mary Fletcher-Louis as head of consulting and chief operations officer. Fletcher-Louis has been working in roles across the pharmaceutical industry for more than 25 years, providing consulting and strategic leadership to clients around the world. Prior to joining CREATION.co, she was vice president at DRG Abacus, where she led the company’s value communication centre of excellence.
Ketchum
Conor Nash
Ketchum has appointed Conor Nash as global chief financial officer and chief operating officer. Nash brings more than 20 years of financial and operational experience to the consultancy, which he joins from WPP. During his time there, he held a variety of commercial, operational and financial leadership roles at the holding company level and at agencies such as Ogilvy and Grey.
Fishawack Health
Mario Muredda
Fishawack Health has appointed Mario Muredda as president of marketing. Muredda brings a wealth of experience leading healthcare marketing agencies, and joins the company after most recently serving as chief executive officer at Harrison and Star. During his time there, Muredda worked his way up from the role of senior vice president, director of client services, which he assumed in 2012.
Envision Pharma Group
Pauline Bernard
Envision Pharma Group has appointed Pauline Bernard as regional head, commercial strategy, Japan Asia-Pacific. Bernard has over 30 years’ experience working in healthcare in JAPAC. Over the course of her career, she has worked across several commercial and leadership functions within top multinational pharmaceutical companies, and most recently in a management consulting practice with a focus on digital technology.
Langland
JP Racle
Langland has appointed JP Racle as design director. Racle joins the agency from Grey London, where he held the position of head of digital content and experience, having established the digital department from the ground up. Racle will run a large, integrated design team that spans the four disciplines of clinical trial experience, medical strategy and education, public relations and policy, and advertising.
Saatchi & Saatchi Wellness
Nanda Marth
Saatchi & Saatchi Wellness has appointed Nanda Marth as creative director. Marth brings over 20 years’ experience to her new role, having worked in healthcare advertising encompassing roles based in the US, Brazil and the UK. She was previously executive creative director at VMLY&Rx London and was Creative Director at Havas SO. Other previous roles also include those at Grey Group and Langland.
Digitas Health
Matt Turrell
Digitas Health has appointed Matt Turrell as creative director. A previous Cannes Lions Health and NYF Global Grand Prix winner, Turrell joins Digitas with extensive experience spanning integrated marketing, advertising and design, having held creative director roles at McCann Health, Langland and Saatchi & Saatchi, among others. Turrell will be leading the agency’s digital-first creative offering.
90TEN
Lewis Picton
90TEN has appointed Lewis Picton as senior account manager. Picton joins the consultancy’s communications team following four years in healthcare comms, gaining experience working with pharmaceutical and medtech companies. He most recently served as senior account manager at Say Communications, having joined the company as a junior account executive.
90TEN
Jasmine Belfiore
90TEN has appointed Jasmine Belfiore as senior account executive. Belfiore has an academic background in neuroscience and three years of experience in medical communications. She joins the consultancy from SciMentum in her most recent role as account executive, a position she assumed in June 2020 after joining the company a few months prior as a medical communications trainee.
90TEN
Tom Clare-Ducler
90TEN has appointed Tom Clare-Ducler as account executive. Clare-Ducler joins the consultancy with a degree in psychology from Goldsmiths, University of London, and he also has experience working in private healthcare. He was previously a customer relationship manager at Roodlane Medical and also spent time in Paris as Head Teacher of the Paris American Academy.